EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors
Data published in Journal of Pharmacology and Experimental Therapeutics NodThera’s brain-penetrant NLRP3 inhibitors matched weight loss driven by GLP-1 receptor agonist semaglutide (Wegovy®)
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin,